Overview
Opdivo is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of bladder cancer, called urothelial carcinoma. It can be used after surgery to lower the risk of the cancer coming back in…

Overview
Padcev is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of bladder cancer. It is approved in combination with pembrolizumab (Keytruda) or with pembrolizumab and berahyaluronidase…

Overview
Tepadina is approved by the U.S. Food and Drug Administration (FDA) for the treatment of superficial papillary carcinoma of the urinary bladder, a form of bladder cancer. This treatment is typically used for…

Overview
Tice BCG is approved by the U.S. Food and Drug Administration (FDA) to treat and prevent carcinoma in situ (CIS, a type of bladder cancer that stays on the bladder lining). It is also used to prevent the…

Overview
Valstar is approved by the U.S. Food and Drug Administration (FDA) to treat carcinoma in situ (CIS), a type of bladder cancer that has not spread beyond the bladder lining, in people who did not respond to…

Overview

Zusduri is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (NMIBC). It is indicated for people…